Insmed Incorporated (NASDAQ:INSM) CFO Sara Bonstein Sells 3,470 Shares

Insmed Incorporated (NASDAQ:INSM) CFO Sara Bonstein sold 3,470 shares of the business’s stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $65.70, for a total transaction of $227,979.00. Following the sale, the chief financial officer now directly owns 114,736 shares of the company’s stock, valued at $7,538,155.20. This represents a 2.94 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Sara Bonstein also recently made the following trade(s):

• On Friday, January 10th, Sara Bonstein sold 1,066 shares of Insmed stock. The shares were sold at an average price of $63.72, for a total transaction of $67,925.52.

Insmed Stock Down 0.7 %

NASDAQ INSM traded down $0.47 during trading on Friday, hitting $65.25. The company’s stock had a trading volume of 3,087,759 shares, compared to its average volume of 1,881,810. Insmed Incorporated has a fifty-two week low of $21.92 and a fifty-two week high of $80.53. The company has a market cap of $11.67 billion, a PE ratio of -11.76 and a beta of 1.12. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. The business’s 50 day simple moving average is $71.29 and its 200-day simple moving average is $72.44.

Insmed (NASDAQ:INSM) last released its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share for the quarter, missing the consensus estimate of ($1.19) by ($0.08). The business had revenue of $93.40 million for the quarter, compared to the consensus estimate of $93.36 million. The company’s revenue was up 18.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.10) earnings per share. On average, equities analysts anticipate that Insmed Incorporated will post -5.44 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have commented on INSM. JPMorgan Chase & Co. raised their price objective on Insmed from $74.00 to $83.00 and gave the stock an “overweight” rating in a report on Friday, November 22nd. Bank of America lifted their price objective on Insmed from $84.00 to $86.00 and gave the company a “buy” rating in a report on Wednesday, October 9th. HC Wainwright reiterated a “buy” rating and set a $90.00 target price on shares of Insmed in a report on Friday, November 1st. Finally, Truist Financial reaffirmed a “buy” rating and issued a $105.00 price target (up previously from $100.00) on shares of Insmed in a research report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $83.67.

Hedge Funds Weigh In On Insmed

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Darwin Global Management Ltd. acquired a new position in shares of Insmed in the second quarter valued at about $237,076,000. Vestal Point Capital LP boosted its position in Insmed by 113.3% in the third quarter. Vestal Point Capital LP now owns 1,600,000 shares of the biopharmaceutical company’s stock valued at $116,800,000 after buying an additional 850,000 shares during the last quarter. Clearbridge Investments LLC increased its holdings in Insmed by 76.8% in the 2nd quarter. Clearbridge Investments LLC now owns 1,644,948 shares of the biopharmaceutical company’s stock worth $110,212,000 after buying an additional 714,539 shares during the period. Farallon Capital Management LLC purchased a new position in Insmed during the 2nd quarter worth approximately $38,056,000. Finally, Fred Alger Management LLC acquired a new stake in Insmed during the 2nd quarter valued at approximately $33,404,000.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.